NasVax Announces Presentation at Biotech Showcase and J.P. Morgan Healthcare Conferences

NESS ZIONA, Israel, January 10, 2011 /PRNewswire-FirstCall/ -- NasVax Ltd. (TASE: NSVX), a leading company in the development of improved vaccine and immunotherapeutics, announced today that Dr. Rom Eliaz, CEO, will participate in the J.P. Morgan 29th Annual Healthcare Conference and will present at the Biotech Showcase, at 9:30 am PST/12:30 noon EST on January 12, 2011. Dr. Eliaz will present a corporate overview on NasVax and also will join some of the world's leading infectious disease companies in the CEO panel entitled "Infectious Disease: A War on Many Fronts - Can it be won?" in the Biotech Showcase conference held in San Francisco January 10-12, 2011.

                                   Nasvax Presentation

                     Parc 55 Wyndham Hotel, 4th Floor, Stockton Room

                             January 12, 2011 at 9:30 am PST

                                          Panel

             "Infectious Disease Workshop: A War on Many Fronts - Can it be
                                        won?"

                                  Parc 55 Wyndham Hotel

                    Wednesday, January 12, 2011, 8:00am - 9:00am PST

                          http://www.ebdgroup.com/bts/index.php

About NasVax Ltd.

NasVax develops improved vaccines and immunotherapeutic products. The company has four distinct product development programs. Oral anti-CD3 immunotherapy employs a monoclonal antibody (MAb) that down-regulates pathogenic immune cells in inflammatory and autoimmune diseases, with a Phase 2a trial ongoing for NASH. VaxiSome(R) is an adjuvant / delivery system for enhancing immunogenicity of vaccines and immunotherapeutics; NasVax is working with Novartis in a non-exclusive Research and Option-for-License Agreement on applying VaxiSome(R) to Novartis' influenza and another vaccine target. The group-common protein-based pneumococcal vaccine in preclinical studies is a third-generation product with potential improvements over current pneumococcal vaccines, with a set of new antigens that is the focus of an exclusive Research and Option-for-License Agreement with GlaxoSmithKline. BBS for Alzheimer's disease is an immunotherapeutic MAb with a distinctive mechanism of action that could offer safety and efficacy advantages over other immunotherapeutic approaches. The Company is headquartered in Ness Zionna, Israel and is traded on the TASE under the symbol NSVX. For more information about the Company and its programs, visit http://www.nasvax.com.

    Contact: Rom Eliaz, PhD., MBA
    CEO
    NasVax Ltd
    Phone +972-8-9396577
    E-mail : [email protected]
    Web: http://www.nasvax.com

SOURCE Nasvax Ltd